This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While advances in treatment have reduced mortality in some regions, the atherosclerosis prevention remains challenging. This shift results from an epidemiologic transition: as infectious diseases decline, chronic conditions like atherosclerosis dominate.
High blood pressure, also known as hypertension, is a common condition that affects millions of people worldwide. Often referred to as the silent killer, hypertension can quietly damage your heart and other vital organs over time. Hypertension is diagnosed when blood pressure consistently reads 130/80 mm Hg or higher.
The EAS 2024 Congress (May 26-29, 2024) has concluded, providing critical insights into atherosclerosis and related vascular disease. Shapiro (United States of America) focused on preventing atherosclerosis over myocardial infarction, suggesting that CAC’s late-stage detection does not fit classic definitions of primary prevention.
Don’t worry—you can still access the 19th Annual CMHC sessions through our On-Demand platform, which offers 14 CME credits across four comprehensive tracks: Cardiorenal Health: Stay up-to-date with the latest on therapies for resistant hypertension, chronic kidney disease markers, and cardiac risk assessment tools.
Recently, indisputable evidence has shown that the TyG index is strongly associated with cardiovascular disease [CVD, including atherosclerosis, heart failure (HF), and hypertension] prognosis and mortality. Finally, we summarized the mechanism of the “obesity paradox.”
Innovations in Cardiorenal Metabolic Medicine The event will focus on the whole spectrum of cardiorenal metabolic disease, including obesity, diabetes, lipids, hypertension, and cardiorenal disease. Michos, MD, MHS, FACC, FAHA, FASE, FASPC ; famed hypertension expert Keith C.
Inflammation: Genetic variations can make some people more prone to chronic inflammation, which contributes to the development of atherosclerosis. Maintain a Healthy Weight: Obesity amplifies the effects of genetic predispositions by contributing to high cholesterol, hypertension, and diabetes.
Excess salt in the diet was indicated as a recognized risk factor in the case of hypertension 82.4%, atrial fibrillation 28.8%, obesity 36.4%, type 2 diabetes 20.4%, lipid disorders 18.5%, heart failure 59.1%, stroke 56.9%, and atherosclerosis 42.2%. to even 53%.
The prevalence of HF risk factors was high: hypertension, 61.9%; former or current smoking, 53.7%; obesity 34.8%; diabetes; 24.7%; and chronic kidney disease; 22%. Results:Median age was 73 (25th–75th percentile 67–81) years, 53.2% were female, 25.6% were Black, 12.8% were Chinese, and 40.0% were White.
Keynote speaker and atherosclerosis expert Peter Libby, MD , captivated the audience with an update on his research into inflammation and atherosclerosis. He discussed therapeutic options not only for treating atherosclerosis but also for preventing cardiovascular disease. Experts like Louis J.
SUMMIT Trial : Weekly subcutaneous tirzepatide showed significant reductions in CV death and HF-related events among patients with HFpEF and obesity. Read the published study. Access the full study. OPTION Trial : LAAC after AFib ablation was associated with lower risks of major bleeding compared to oral anticoagulation.
While this response is adaptive in the short term, chronic stress keeps your blood pressure elevated for extended periods, increasing your risk of hypertension (high blood pressure) and its associated complications, such as heart disease and stroke.
2023, the American Heart Association (AHA) issued a presidential advisory on the urgency of this systemic disorder involving heart disease, kidney disease, diabetes and obesity. In its advisory, the AHA stressed an interdisciplinary team approach emphasizing social determinants of health, shortcomings in current efforts, and knowledge gaps.
The model consisted of six variables, and one point was awarded for each: atrial fibrillation, large artery atherosclerosis, large vessel occlusion, obesity, prior anti-hypertensive medication usage and if patients age was 18-39 or > 69. Risk of positive findings was 6.2% for score of 0, 26.1% for score of 1, 65.0%
A 69‐year‐old woman with a history of lung cancer, hypertension, chronic tobacco use, atherosclerosis, and known calcified plaque at the left carotid bifurcation on dual antiplatelet therapy presented with acute onset of expressive aphasia and right hemiparesis due to acute left CCAO.
Factors such as smoking, high blood pressure, high cholesterol levels, obesity, and a sedentary lifestyle significantly increase the risk of developing cardiovascular disease. Over time, chronic stress can lead to the development of conditions like hypertension and heart disease.
Introduction:It is known that past the age of 35, the prevalence of large artery atherosclerosis (LAA) related strokes increases with a cardiovascular risk factor (CVRF) profile beginning to resemble that of elderly patients. A significantly larger proportion of patients with LAA had baseline CVRFs including hypertension (80.0%
This study explores whether midlife vascular risk factors are associated with risk of PDD in the community-based ARIC cohort.Methods:ARIC participants were evaluated for vascular risk factors (hypertension, diabetes, hypercholesterolemia, smoking, and obesity) in 1987-1989 (ages 44-64) and followed through 2016.
This study examined associations of midlife vascular risk factors (VRFs), and the cumulative burden of these factors, with LLD.Methods:Individuals from the Atherosclerosis Risk in Communities (ARIC) Study were evaluated for VRFs (smoking, hypertension, diabetes, hypercholesterolemia, and obesity) at midlife (ages 44-66).
APOB The fundamental basis of coronary artery disease is when a cholesterol particle is retained in the artery wall, and an inflammatory cascade occurs, resulting in the formation of atherosclerosis. Share Visceral Adipose Tissue The real risk of obesity comes from the inflammatory engine of visceral fat found in the abdominal cavity.
6 [link] Insufficient sleep has been linked to a greater risk for several health conditions including obesity, diabetes, hypertension, and cognitive decline. The amount of calcium in the blood vessels (known as arterial calcification), a marker of subclinical atherosclerosis, is higher in people with a short sleep duration.
Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection. In the U.S.,
ObjectiveMitochondrial dysfunction is associated with increased risk of atherosclerosis by disrupting key cellular processes that contribute to premature vascular ageing. EOCAD patients had lower mtDNA-CN (p<0.001) and higher mtDNA4977 deletion (p=0.026).
Diabetes and Obesity Care Advancements New Technologies for Diabetes Management : The recent FDA approvals of various insulin delivery devices, including the Embecta patch pump for Type 2 diabetes , have expanded patient options. These findings strengthen the case for broader utilization of finerenone in heart failure management.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content